FOLH1 and prostate carcinoma: Additionally, a first-in-human phase I trial of castration-resistant prostate cancer directed CAR T cells, targeting PSMA, and equipped with a dominant negative TGFβ receptor looked to determine the safety, bioactivity, and disease response.